Methylation-associated inactivation of LATS1 and its effect on demethylation or overexpression on YAP and cell biological function in human renal cell carcinoma

International Journal of Oncology

Volumn 45, Issue 6, 2014, Pages 2511-2521

  Chen, Ke Hong ^a   He, Jiang ^a   Wang, De Lin ^a   Cao, Jian Jia ^a   Li, Mei Cai ^a   Zhao, Xiu Min ^a   Sheng, Xia ^a   Li, Wen Bin ^a   Liu, Wu Jiang ^b  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

Demethylation; Hippo; LATS1; Methylation; Renal cell carcinoma; YAP

Indexed keywords

AZACITIDINE; LATS1 PROTEIN, HUMAN; MESSENGER RNA; PHOSPHOPROTEIN; PROTEIN SERINE THREONINE KINASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR SUPPRESSOR PROTEIN; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

ADULT; AGED; APOPTOSIS; BIOSYNTHESIS; CELL PROLIFERATION; DNA METHYLATION; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; KIDNEY CARCINOMA; MALE; MIDDLE AGED; PATHOLOGY; PROMOTER REGION; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; APOPTOSIS; AZACITIDINE; CARCINOMA, RENAL CELL; CELL PROLIFERATION; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; PHOSPHOPROTEINS; PROMOTER REGIONS, GENETIC; PROTEIN-SERINE-THREONINE KINASES; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84907687668     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2687     Document Type: Article

References (54)

1. Junker K, Ficarra V, Kwon ED, Leibovich BC, Thompson RH and Oosterwijk E: Potential role of genetic markers in the management of kidney cancer. Eur Urol 63:333-340, 2013.
2. Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61:212-236, 2011.
3. Linehan WM and Rathmell WK: Kidney cancer. Urol Oncol 30:948-951, 2012.
4. Motzer RJ, Hutson TE, Tomczak P, et al: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584-3590, 2009.
5. Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. New Engl J Med 356:125-134, 2007.
6. Cancer Genome Atlas Research Network: Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499:43-49, 2013.
7. Ricketts CJ, Morris MR, Gentle D, et al: Genome-wide CpG island methylation analysis implicates novel genes in the pathogenesis of renal cell carcinoma. Epigenetics 7:278-290, 2012.
8. Watt F and Molloy PL: Cytosine methylation prevents binding to DNA of a HeLa cell transcription factor required for optimal expression of the adenovirus major late promote. Genes Dev 2:1136-1143, 1988.
9. Zhu WG, Srinivasan K, Dai Z, et al: Methylator of adjacent CpG sites affects Spl/Sp3 binding and activity in the p21 (Cipl) promoter. Mol Cell Biol 23:4056-4065, 2003.
10. Morris MR, Ricketts C, Gentle D, et al: Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma. Oncogene 29:2104-2117, 2010.
11. Reu FJ, Leaman DW, Maitra RR, et al: Expression of RASSF1A, an epigenetically silenced tumor suppressor, overcomes resistance to apoptosis induction by interferons. Cancer Res 66:2785-2793, 2006.
12. Zhang Q, Ying J, Zhang K, et al: Aberrant methylation of the 8p22 tumor suppressor gene DLC1 in renal cell carcinoma. Cancer Lett 249:220-226, 2007.
13. Kondratov AG, Stoliar LA, Kvasha SM, et al: Methylation pattern of the putative tumor-suppressor gene LRRC3B promoter in clear cell renal cell carcinomas. Mol Med Rep 5:509-512, 2012.
14. Justice RW, Zilian O, Woods DF, Noll M and Bryant PJ: The Drosophila tumor suppressor gene warts encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation. Genes Dev 9:534-546, 1995.
15. Ji T, Liu D, Shao W, Yang W, Wu H and Bian X: Decreased expression of LATS1 is correlated with the progression and prognosis of glioma. J Exp Clin Cancer Res 31:67, 2012.
16. Zhao B, Tumaneng K and Guan KL: The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nat Cell Biol 13:877-883, 2011.
17. Yu T, Bachman J and Lai ZC: Evidence for a tumor suppressor role for the large tumor suppressor genes LATS1 and LATS2 in human cancer. Genetics 195:1193-1196, 2013.
18. Visser-Grieve S, Zhou Z, She YM, Huang H, Cyr TD, Xu T and Yang X: LATS1 tumor suppressor is a novel actin-binding protein and negative regulator of actin polymerization. Cell Res 21:1513-1516, 2011.
19. Yabuta N, Mukai S, Okamoto A, et al: N-terminal truncation of Latsl causes abnormal cell growth control and chromosomal instability. J Cell Sci 126:508-520, 2013.
20. Visser S and Yang X: Identification of LATS transcriptional targets in HeLa cells using whole human genome oligonucleotide microarray. Gene 449:22-29, 2010.
21. Zhou GX, Li XY, Zhang Q, et al: Effects of the hippo signaling pathway in human gastric cancer. Asian Pac J Cancer Prev 14:5199-5205, 2013.
22. Nishio M, Hamada K, Kawahara K, et al: Cancer susceptibility and embryonic lethality in Mobla/lb double-mutant mice. J Clin Invest 122:4505-4518, 2012.
23. Zhao B, Li L, Wang L, Wang CY, Yu J and Guan KL: Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes Dev 26:54-68, 2012.
24. St John MA, Tao W, Fei X, et al: Mice deficient of Latsl develop soft-tissue sarcomas, ovarian tumours and pituitary dysfunction. Nat Genet 21:182-186, 1999.
25. Yu FX and Guan KL: The Hippo pathway: regulators and regulations. Genes Dev 27:355-371, 2013.
26. Wierzbicki PM, Adrych K, Kartanowicz D, et al: Underexpression of LATS1 TSG in colorectal cancer is associated with promoter hypermethylation. World J Gastroenterol 19:4363-4373, 2013.
27. Steinmann K, Sandner A, Schagdarsurengin U and Dammann RH: Frequent promoter hypermethylation of tumor-related genes in head and neck squamous cell carcinoma. Oncol Rep 22:1519-1526, 2009.
28. Seidel C, Schagdarsurengin U, Bltimke K, et al: Frequent hypermethylation of MST1 and MST2 in soft tissue sarcoma. Mol Carcinog 46:865-871, 2007.
29. Jiang Z, Li X, Hu J, Zhou W, Jiang Y, Li G and Lu D: Promoter hypermethylation-mediated down-regulation of LATS1 and LATS2 in human astrocytoma. Neurosci Res 56:450-458, 2006.
30. Takahashi Y, Miyoshi Y, Takahata C, Irahara N, Taguchi T, Tamaki Y and Noguchi S: Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clin Cancer Res 11:1380-1385, 2005.
31. Tao Q, Huang H, Geiman TM, Lim CY, Fu L, Qiu GH and Robertson KD: Defective de novo methylation of viral and cellular DNA sequences in ICF syndrome cells. Hum Mol Genet 11:2091-2102, 2002.
32. Hisaoka M, Tanaka A and Hashimoto H: Molecular alterations of h-warts/LATSl tumor suppressor in human soft tissue sarcoma. Lab Invest 82:1427-1435, 2002.
33. Nishio M, Otsubo K, Maehama T, Mimori K and Suzuki A: Capturing the mammalian Hippo: elucidating its role in cancer. Cancer Sci 104:1271-1277, 2013.
34. Bao Y, Hata Y, Ikeda M and Withanage K: Mammalian Hippo pathway: from development to cancer and beyond. J Biochem 149:361-379, 2011.
35. Schlegelmilch K, Mohseni M, Kirak O, et al: Yapl acts downstream of a-catenin to control epidermal proliferation. Cell 144:782-795, 2011.
36. Moleirinho S, Chang N, Sims AH, et al: KIBRA exhibits MST-independent functional regulation of the Hippo signaling pathway in mammals. Oncogene 32:1821-1830, 2013.
37. Angus L, Moleirinho S, Herron L, et al: Willin/FRMD6 expression activates the Hippo signaling pathway kinases in mammals and antagonizes oncogenic YAP. Oncogene 31:238-250, 2011.
38. Badouel C and McNeill H: SnapShot: the hippo signaling pathway. Cell 145:484-484, 2011.
39. Visser S and Yang X: LATS tumor suppressor, a new governor of cellular homeostasis. Cell Cycle 9:3892-3903, 2010.
40. Salah Z, Cohen S, Itzhaki E and Aqeilan RI: NEDD4 E3 ligase inhibits the activity of the Hippo pathway by targeting LATS1 for degradation. Cell Cycle 12:3817-3823, 2013.
41. Serrano I, McDonald PC, Lock F, Muller WJ and Dedhar S: Inactivation of the Hippo tumour suppressor pathway by integrin-linked kinase. Nat Commun 4:2976, 2013.
42. Mo JS, Yu FX, Gong R, Brown JH and Guan KL: Regulation of the Hippo-YAP pathway by protease-activated receptors (PARs). Genes Dev 26:2138-2143, 2012.
43. Yu FX, Zhao B, Panupinthu N, et al: Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell 150:780-791, 2012.
44. Noviello C, Courjal F and Theillet C: Loss of heterozygosity on the long arm of chromosome 6 in breast cancer: possibly four regions of deletion. Clin Cancer Res 2:1601-1606, 1996.
45. Lee EY, To H, Shew JY, Bookstein R, Scully P and Lee WH: Inactivation of the retinoblastoma susceptibility gene in human breast cancers. Science 241:218-221, 1988.
46. Morinaga N, Shitara Y, Yanagita Y, et al: Molecular analysis of the h-warts/LATSl gene in human breast cancer. Int J Oncol 17:1125-1129, 2000.
47. Hong W and Guan KL: The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway. Semin Cell Dev Biol 23:785-793, 2012.
48. Hergovich A: Regulation and functions of mammalian LATS/NDR kinases: looking beyond canonical Hippo signalling. Cell Biosci 3:32, 2013.
49. Valis K, Prochazka L, Boura E, et al: Hippo/Mstl stimulates transcription of the proapoptotic mediator NOXA in a FoxOl-dependent manner. Cancer Res 71:946-954, 2011.
50. Yang X, Li DM, Chen W and Xu T: Human homologue of Drosophila lats, LATS1, negatively regulate growth by inducing G (2)/M arrest or apoptosis. Oncogene 20:6516-6523, 2001.
51. Matallanas D, Romano D, Al-Mulla F, et al: Mutant K-Ras activation of the proapoptotic MST2 pathway is antagonized by wild-type K-Ras. Mol Cell 44:893-906, 2011.
52. Hori T, Takaori-Kondo A, Kamikubo Y and Uchiyama T: Molecular cloning of a novel human protein kinase, kpm, that is homologous to warts/lats, a Drosophila tumor suppressor. Oncogene 19:3101-3109, 2000.
53. Li XJ, Park ES, Park MH and Kim SM: 3, 3'-Diindolylmethane suppresses the growth of gastric cancer cells via activation of the Hippo signaling pathway. Oncol Rep 30:2419-2426, 2013.
54. Xia H, Qi H, Li Y, et al: LATS1 tumor suppressor regulates G2/M transition and apoptosis. Oncogene 21:1233-1241, 2002.